You certainly would be inspected and reviewed according to the principles of the 211, and Q7A provides additional guidance. Part of the issue would be – is the product that is intended to be marketed in the U.S. going to be a licensed biological product or something that’s regulated by the Center for Drugs? The other consideration for a licensed biological is have we licensed the product from start to finish?